This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
7
episodes
1h 02m
Details
Presenters
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires faculty and all individuals who can influence content to disclose any real or apparent financial relationships related to this activity. GLC has implemented processes to identify and mitigate potential conflicts of interest, ensuring independence, objectivity, balance, and scientific rigor prior to the activity.
The following faculty and planners have disclosed any relevant financial relationships with ineligible companies within the past 24 months.
Chair:
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Director, Inflammatory Bowel Disease Center
University of Chicago
Chicago, IL
Advisor/Consultant: AbbVie, Abivax SA, AltruBio, Athos Therapeutics, Inc., Bristol Myers Squibb, Celltrion, Connect Biopharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, Ventyx
Contracted Researcher: Takeda Pharmaceuticals
Faculty:
Michael Dolinger, MD, MBA
Director of Pediatric IBD, Department of Pediatrics
NYU Langone Health
NYU Grossman School of Medicine
New York, NY
Ownership interest: Dova Health
Consulting Fees: AbbVie, Celltrion, Johnson & Johnson, Neurologica Corp. (a subsidiary of Samsung Electronics Co., Ltd.), Pfizer, Sanofi, Takeda
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Johns Hopkins University
Department of Medicine
Division of Gastroenterology & Hepatology
Lutherville, MD
Consulting Fees: AbbVie, Janssen (Johnson & Johnson), Takeda
Ugo Iroku, MD, MHS
Assistant Professor of Clinical Medicine
Icahn School of Medicine at Mount Sinai
Gastroenterologist, Summit Health
New York, NY
Consulting Fees: AbbVie, Johnson & Johnson
Florence-Damilola Odufalu, MD
Assistant Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, CA
Consulting Fees: AbbVie, Janssen, Johnson & Johnson, Pfizer
Reviewers/Content Planners/Authors:- Tim Person has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Define the association between irritable bowel disease (IBD) pathophysiology and targets of treatment
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists and advanced practice providers as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with irritable bowel disease.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) and Chron’s Colitis Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-048-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until 05.01.27. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by independent educational grants from AbbVie, Inc., Genentech Inc., Johnson & Johnson, and Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.Publication Dates
Release Date:
Expiration Date:
